Stockscreener 앱 받기
59.02
0.17%
0.10
시간 외 거래:
59.02
전일 마감가:
$58.92
열려 있는:
$59.45
하루 거래량:
1.28M
Relative Volume:
0.98
시가총액:
$8.78B
수익:
-
순이익/손실:
$-946.53M
주가수익비율:
-8.4721
EPS:
-6.9664
순현금흐름:
$-814.94M
1주 성능:
-0.32%
1개월 성능:
-5.75%
6개월 성능:
+7.86%
1년 성능:
+76.34%
1일 변동 폭
$58.78
$59.96
1주일 범위
$57.01
$61.50
52주 변동 폭
$31.89
$65.00
백스사이트 Stock (PCVX) Company Profile
명칭
Vaxcyte Inc
전화
650-837-0111
주소
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
59.02 | 8.85B | 0 | -946.53M | -814.94M | -6.9664 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
백스사이트 Stock (PCVX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재확인 | Needham | Buy |
| 2025-09-12 | 개시 | Goldman | Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 개시 | Goldman | Buy |
| 2023-12-07 | 개시 | Mizuho | Buy |
| 2023-04-18 | 개시 | TD Cowen | Outperform |
| 2023-01-03 | 재확인 | Needham | Buy |
| 2022-12-15 | 개시 | Guggenheim | Buy |
| 2022-11-17 | 개시 | BTIG Research | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-24 | 재개 | Jefferies | Buy |
| 2020-07-07 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 개시 | Needham | Buy |
모두보기
백스사이트 주식(PCVX)의 최신 뉴스
Trading the Move, Not the Narrative: (PCVX) Edition - Stock Traders Daily
Vaxcyte EVP Jim Wassil sells $163,862 in company stock By Investing.com - Investing.com South Africa
Vaxcyte CFO Andrew Guggenhime Forfeits 7,155 Shares, 7% of Holdings at $60.36 Each - Kalkine Media
Vaxcyte EVP Jim Wassil sells $163,862 in company stock - Investing.com
Vaxcyte (PCVX) officer plans stock sale after RSU vest - Stock Titan
Vaxcyte at Cantor conference: broad vaccine bet nears key test By Investing.com - Investing.com Canada
PCVX: VAX-31 phase III data expected by end of October, targeting broader pneumococcal protection - TradingView
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes By Investing.com - Investing.com Nigeria
Why Are Vaxcyte (NASDAQ:PCVX) Shares Under Pressure After A Timeline Update? - Kalkine Media
Vaxcyte Executive Sells Shares for Tax Obligations - Intellectia AI
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - The Motley Fool
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know - The Globe and Mail
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm - The Motley Fool
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm - The Motley Fool
Vaxcyte (PCVX) Stock Price, News & Analysis - MarketBeat
Vaxcyte, Inc. (PCVX) Stock Analysis: Examining a Potential 78% Upside in the Biotech Frontier - DirectorsTalk Interviews
Vaxcyte (PCVX) Sets Phase 3 Pneumococcal Vaccine Data Release, M - GuruFocus
Vaxcyte narrows timing for pivotal VAX-31 data to late October (PCVX:NASDAQ) - Seeking Alpha
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble - Yahoo Finance
Leadership Hires and OPUS-1 Timeline Could Be A Game Changer For Vaxcyte (PCVX) - simplywall.st
Vaxcyte Stock Price Forecast. Should You Buy PCVX? - StockInvest.us
Vaxcyte Appoints New Chief Medical Officer, Updates Trial Timeline - The Globe and Mail
Vaxcyte (NASDAQ: PCVX) officer plans new stock sale after recent trades - Stock Titan
Vaxcyte Inc. (PCVX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Vaxcyte stock jumps on new executives, VAX-31 data timeline - investing.com
Vaxcyte stock jumps on new executives, VAX-31 data timeline By Investing.com - Investing.com Australia
Vaxcyte Appoints Chief Medical Officer And Chief Legal Officer Narrows Guidance For Expected Vax-31 Opus-1 Topline Data - TradingView
Vaxcyte appoints two executives, narrows trial timeline By Investing.com - Investing.com Canada
Vaxcyte Inc (PCVX) Updates Phase 3 Trial Timeline, Market Pricin - GuruFocus
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data - Investing News Network
Vaxcyte appoints two executives, narrows trial timeline - investing.com
Vaxcyte, Inc. Announces Management Changes - marketscreener.com
Vaxcyte COO Jim Wassil sells over $212,000 in company stock By Investing.com - Investing.com South Africa
Vaxcyte Appoints Chief Medical Officer and Chief Legal - GlobeNewswire
Vaxcyte COO Jim Wassil sells over $212,000 in company stock - investing.com
(PCVX) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Vaxcyte Options Spot-On: On September 1st, 90,099 Contracts Were Traded, With 97,138 Open Interest - Moomoo
Vaxcyte (NASDAQ: PCVX) officer lines up new stock sale after recent trades - Stock Titan
Vaxcyte, Inc. (PCVX) Investor Outlook: Biotech Stock With An 82% Potential Upside - DirectorsTalk Interviews
Vaxcyte Inc. (PCVX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Vaxcyte Inc. (PCVX) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Vaxcyte (PCVX) Pulls Back 2.2% to $59.84, Approaches Key Support at $56.85Volume Gap - vinanet.vn
Vaxcyte to Participate in Upcoming Investor Conferences - manilatimes.net
백스사이트 (PCVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
백스사이트 주식 (PCVX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wassil Jim | EVP, Chief Scientific Ofc, COO |
Sep 09 '26 |
Sale |
59.52 |
1,334 |
79,401 |
145,435 |
0.14%
0.15%
자본화:
|
볼륨(24시간):